Diet switch and omega-3 hydroxy-fatty acids display differential hepatoprotective effects in an obesity/nonalcoholic fatty liver disease model in mice

World J Gastroenterol. 2018 Jan 28;24(4):461-474. doi: 10.3748/wjg.v24.i4.461.

Abstract

Aim: To study the effect of 18-hydroxy-eicosapentaenoic acid (18-HEPE) and 17-hydroxy-docosahexaenoic acid (17-HDHA) in a murine model of obesity/nonalcoholic fatty liver disease.

Methods: C57BL/6 mice were fed with standard chow diet (CD) or high-fat, fructose-enriched diet (HFD) for 16 wk. Then, three groups were treated for 14 d with either, diet switch (HFD for CD), 18-HEPE, or 17-HDHA. Weight and fasting glucose were recorded on a weekly basis. Insulin tolerance test was performed at the end of treatment. Histological analysis (HE and Masson's trichrome stain) and determination of serum insulin, glucagon, glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide, adiponectin and resistin were carried out as well as liver proteins by western blot.

Results: Mice treated with hydroxy-fatty acids 18-HEPE and 17-HDHA displayed no weight loss or improved insulin sensitivity. However, these mice groups showed a significant amelioration on serum GLP-1, adiponectin and resistin levels. Also, a significant reduction on inflammatory infiltrate was observed at both portal and lobular zones. Furthermore, up-regulation of PPARα/γ protein levels was observed in liver tissue and it was associated with decreased levels of NF-κB also determined by western blot analysis. On the other hand, diet switch regimen resulted in a marked improvement in most parameters including: weight loss, increased insulin sensitivity, decreased steatosis, restored levels of insulin, glucagon, leptin, adiponectin and resistin. However, no significant changes were observed regarding inflammatory infiltrate in this last group.

Conclusion: 18-HEPE and 17-HDHA differentially exert hepatoprotective effects through up-regulation of nuclear receptors PPARα/γ and amelioration of serum adipokines profile.

Keywords: 17-hydroxy-docosahexaenoic acid; 18-hydroxy-eicosapentaenoic acid; Nonalcoholic fatty liver disease; Obesity; Polyunsaturated fatty acids.

MeSH terms

  • Animals
  • Blood Glucose / analysis
  • Blood Glucose / drug effects
  • Diet, High-Fat / adverse effects
  • Dietary Carbohydrates / adverse effects
  • Disease Models, Animal
  • Docosahexaenoic Acids / pharmacology
  • Docosahexaenoic Acids / therapeutic use*
  • Eicosapentaenoic Acid / analogs & derivatives*
  • Eicosapentaenoic Acid / pharmacology
  • Eicosapentaenoic Acid / therapeutic use
  • Fructose / adverse effects
  • Glucagon-Like Peptide 1 / blood
  • Humans
  • Liver / drug effects
  • Liver / metabolism
  • Liver / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Non-alcoholic Fatty Liver Disease / blood
  • Non-alcoholic Fatty Liver Disease / etiology
  • Non-alcoholic Fatty Liver Disease / pathology
  • Non-alcoholic Fatty Liver Disease / therapy*
  • Obesity / blood
  • Obesity / etiology
  • Obesity / pathology
  • Obesity / therapy*
  • Protective Agents / pharmacology
  • Protective Agents / therapeutic use*
  • Weight Loss / drug effects

Substances

  • 18(R)-hydroxyeicosapentaenoic acid
  • Blood Glucose
  • Dietary Carbohydrates
  • Protective Agents
  • Docosahexaenoic Acids
  • Fructose
  • Glucagon-Like Peptide 1
  • 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid
  • Eicosapentaenoic Acid